Covid 19 Research using Clinical Trials (Home Page)
HP:0005547: Myeloproliferative disorderHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 Myeloproliferative Neoplasms (MPN) and COVID-19
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.
NCT04385160 Myeloproliferative Neoplasm COVID MeSH:Myeloproliferative Disorders Neoplasms
HPO:Myeloproliferative disorder Neoplasm
Primary Outcomes
Description: Incidence of cases of MPN patients with COVID-19 experiencing pulmonary embolism
Measure: pulmonary embolism (PE) Time: 2 and a half months
Secondary Outcomes
Description: Incidence of cases reporting at least one fatal or non fatal thrombotic event reported in therapy of MPN
Measure: fatal or non fatal thrombotic event Time: 2 and a half months
Description: Incidence of cases reporting at least one COVID-19 worsening outcome as Continuous Positive Airway Pressure (CPAP)
Measure: Continuous Positive Airway Pressure (CPAP) Time: 2 and a half months
Description: Incidence of cases reporting at least one COVID-19 worsening outcome as invasive ventilation
Measure: invasive ventilation Time: 2 and a half months
Description: Incidence of cases reporting at least one COVID-19 worsening outcome as Intensive Care Unit (ICU)
Measure: admission in Intensive Care Unit (ICU) Time: 2 and a half months
Description: incidence of death
Measure: death Time: 2 and a half months
Description: Type of treatments and interventions applied for MPN during COVID-19 and any change reported in therapy of MPN
Measure: treatments and interventions applied for MPN Time: 2 and a half months
Description: Type of treatments and interventions applied for COVID-19
Measure: treatments and interventions applied for COVID-19 Time: 2 and a half months
Description: Odds Ratios (ORs) of the outcome and 95% Confidence Intervals (CIs) associated with patients' characteristics and treatments
Measure: thrombotic events association to patients characteristic and treatments Time: 2 and a half months
2 Observational Study of the Impact of the COronaVirus Disease 2019 (COVID-19) Epidemic on Patients With Myeloproliferative Neoplasias
Primary Outcomes
Description: Incidence of cases of MPN patients with COVID-19 experiencing pulmonary embolism
Measure: pulmonary embolism (PE) Time: 2 and a half monthsSecondary Outcomes
Description: Incidence of cases reporting at least one fatal or non fatal thrombotic event reported in therapy of MPN
Measure: fatal or non fatal thrombotic event Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as Continuous Positive Airway Pressure (CPAP)
Measure: Continuous Positive Airway Pressure (CPAP) Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as invasive ventilation
Measure: invasive ventilation Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as Intensive Care Unit (ICU)
Measure: admission in Intensive Care Unit (ICU) Time: 2 and a half monthsDescription: incidence of death
Measure: death Time: 2 and a half monthsDescription: Type of treatments and interventions applied for MPN during COVID-19 and any change reported in therapy of MPN
Measure: treatments and interventions applied for MPN Time: 2 and a half monthsDescription: Type of treatments and interventions applied for COVID-19
Measure: treatments and interventions applied for COVID-19 Time: 2 and a half monthsDescription: Odds Ratios (ORs) of the outcome and 95% Confidence Intervals (CIs) associated with patients' characteristics and treatments
Measure: thrombotic events association to patients characteristic and treatments Time: 2 and a half monthsThe classic myeloproliferative neoplasias (MNP), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or secondary to PV or ET, are among the most frequent of malignant hemopathies, with overall prevalence estimated at around 10,000 patients followed in France. Due to the median age of patients around 65, the frequency of cardiovascular complications of these thrombogenic diseases and the impact of cytoreductive treatments on immune cells, these patients are considered to be at risk of developing forms severe of COVID-19. This study will assess the impact of MNPs on the risk of developing a severe form of COVID-19, identify new risk factors linked to the disease as well as the impact of treatments for MNPs according to their pharmacological class.
NCT04416438 Myeloproliferative Neoplasm COVID-19 Infection MeSH:Myeloproliferative Disorders
HPO:Myeloproliferative disorder
Primary Outcomes
Description: The crude rate of cumulative incidence of serious infection proven to COVID-19, compared to the population of the same age, same sex, same region of residence during the epidemic period.
Measure: Rate of serious coronavirus infection in different MNP patient subgroups Time: Through inclusion period, an average of 6 months
Description: Number of MNP patients who had COVID-19 compared to general population in France
Measure: Proportion of MNP patients who had COVID-19 infection during the 2020 epidemic. Time: Through inclusion period, an average of 6 months
Description: Number of MNP patients who died from COVID-19
Measure: Rate of death of MNP patients who had COVID-19 Time: Through study completion, an average of 1 year
Description: Number of MNP patients hospitalized in intensive care with need for mechanical ventilation
Measure: Rate of passages in intensive care with need for mechanical ventilation Time: Through study completion, an average of 1 year
HPO Nodes
Primary Outcomes
Description: The crude rate of cumulative incidence of serious infection proven to COVID-19, compared to the population of the same age, same sex, same region of residence during the epidemic period.
Measure: Rate of serious coronavirus infection in different MNP patient subgroups Time: Through inclusion period, an average of 6 monthsDescription: Number of MNP patients who had COVID-19 compared to general population in France
Measure: Proportion of MNP patients who had COVID-19 infection during the 2020 epidemic. Time: Through inclusion period, an average of 6 monthsDescription: Number of MNP patients who died from COVID-19
Measure: Rate of death of MNP patients who had COVID-19 Time: Through study completion, an average of 1 yearDescription: Number of MNP patients hospitalized in intensive care with need for mechanical ventilation
Measure: Rate of passages in intensive care with need for mechanical ventilation Time: Through study completion, an average of 1 year